Gottlieb: New types of drug products may require more medical-device style evaluations

Friday, September 8, 2017

With the coming influx of new types of medical technology like the recently approved gene therapy cancer treatment CAR-T, FDA needs to shift the way it evaluates safety and effectiveness, Commissioner Scott Gottlieb said in a speech Thursday.

Many new products like CAR-T are administered once but have long-term effects, making it hard to evaluate the risk-benefit ratio. As a result, Gottlieb said drug-type products may need to be evaluated in a way that is more similar to FDA's current evaluation process for medical devices, including more emphasis on the post-marketing stage, he said. Sarah points out that the medical device review process is generally shorter and less stringent than the drug approval process. (subscription required)

Media Contacts

Suzanne Ffolkes
VP Communications

Anna Briseño
Senior Manager of Communications

We have health challenges in this country that science will provide answers for if given the chance and we haven't given science that opportunity
Mary Woolley, President and CEO, Research!America